0
0
Home » Pharmaceuticals

Dermatitis (Eczema) – Global Clinical Trials Review, H2, 2021

GlobalData’s clinical trial report provides an overview of the dermatitis (Eczema) clinical trials scenario. This report provides top-line data relating to the clinical trials on Dermatitis (Eczema). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on several ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database -Pharma – clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.

Dermatitis (Eczema) clinical trial report consists of 2278 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 225, 283, 645, 490, and 5 respectively. Similarly, the trials with different status compile of completed – 1536, ongoing – 335, planned – 167, suspended – 9, terminated – 81, and withdrawn – 150. Out of 1536 completed trials 777 trials have achieved endpoint.

What are the market dynamics of the global dermatitis (Eczema) therapeutics clinical trials sector?

The number of dermatitis (eczema) clinical trials conducted globally, has increased by over 881% for the period 2016-2020. As of December 2021, out of 1,536 completed trials, 950 trials have results and 777 trials reached endpoints. There were 925 clinical trials in Phase II, of which 128 clinical trials were in progress for the time period 1995-2021. During the same period, there were 335 clinical trials in progress of which 128 trials were in the Phase II study. The trials that were terminated/suspended or withdrawn accounted for 240. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

Asia-Pacific: In the Asia-Pacific region, Japan has the highest number of dermatitis (eczema) clinical trials followed by India, Australia, South Korea, and China.

Europe: Among the European countries, Germany has the highest number of dermatitis (eczema) clinical trials followed by the Netherlands, France, Poland, and the UK.

North America: The US has the highest number of dermatitis (eczema) clinical trials followed by Mexico and Canada.

Middle East and Africa: Iran has the highest number of dermatitis (eczema) clinical trials followed by Israel, South Africa, Morocco, and Egypt.

Central and South America: Brazil has the highest number of dermatitis (eczema) clinical trials followed by Chile, Colombia, Dominican Republic, and Argentina.

G7 countries: Among the G7 (The US, the UK Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of dermatitis (Eczema) to dermatology clinical trials as of December 2021. In total there were 1,502 clinical trials conducted on dermatitis (Eczema), in G7 countries, of these 515 clinical trials were in the US. During the same period, there were 164 clinical trials in progress and 785 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 90.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of dermatitis (Eczema) to dermatology clinical trials as of December 2021. In total there were 449 clinical trials conducted on dermatitis (Eczema), in E7 countries, of these 214 clinical trials were in China. During the same period, there were 88 clinical trials in progress and 200 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 62.

Global dermatitis (Eczema) therapeutics clinical trials sector, by regions

Global dermatitis (Eczema) therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global dermatitis (Eczema) therapeutics clinical trials sector?

As of December 2021, Novartis AG sponsored the highest number of dermatitis (eczema) clinical trials followed by Pfizer Inc and Sanofi. Other major companies in the sector are LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA.

Global dermatitis (Eczema) therapeutics clinical trials sector, by key companies

Global dermatitis (Eczema) therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key countries The US, Germany, Japan, China, Canada, the UK, South Korea, India, Australia and Poland
Key companies Novartis AG, Pfizer Inc, Sanofi, LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA.

Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
  • The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
  • The Report provides enrollment trends for the past five years
  • Report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional, and country-level.

Key Players

Novartis AG

Pfizer Inc

Sanofi

LEO Foundation

GlaxoSmithKline Plc

Regeneron Pharmaceuticals Inc

Bayer AG

Eli Lilly and Co

Johnson & Johnson

Galderma SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Dermatitis (Eczema) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Source

List of Tables

List of Tables

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Region, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, North America, Top Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2021*

Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2021*

Dermatitis (Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Dermatitis (Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2021*

Dermatitis (Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Dermatitis (Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Phase, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Dermatitis (Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

List of Figures

List of Figures

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Region (%), 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2021*

Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2021*

Dermatitis (Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Dermatitis (Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Dermatitis (Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2021*

Dermatitis (Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Dermatitis (Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Phase (%), 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*

Dermatitis (Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Dermatitis (Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Dermatitis (Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

GlobalData Methodology

Frequently Asked Questions

Key countries in global dermatitis (Eczema) therapeutics clinical trials sector are the US, Germany, Japan, China, Canada, the UK, South Korea, India, Australia, and Poland.

Key companies in global dermatitis (Eczema) therapeutics clinical trials sector are Novartis AG, Pfizer Inc, Sanofi, LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports